FY2025 EPS Estimates for Arvinas Raised by Cantor Fitzgerald

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Arvinas in a research report issued to clients and investors on Tuesday, May 6th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($0.56) per share for the year, up from their prior forecast of ($2.71). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the business posted ($0.97) earnings per share. The company's quarterly revenue was up 646.2% on a year-over-year basis.

ARVN has been the subject of several other research reports. Piper Sandler reiterated an "overweight" rating and set a $14.00 price objective (down previously from $24.00) on shares of Arvinas in a research note on Friday, May 2nd. Truist Financial reiterated a "hold" rating and set a $11.00 price objective (down previously from $21.00) on shares of Arvinas in a report on Monday. Guggenheim dropped their target price on Arvinas from $32.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Barclays decreased their price target on shares of Arvinas from $32.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Finally, Oppenheimer downgraded shares of Arvinas from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 11th. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Arvinas has a consensus rating of "Moderate Buy" and an average price target of $20.97.

Arvinas Stock Performance

Shares of Arvinas stock opened at $6.64 on Thursday. The company has a market capitalization of $484.30 million, a PE ratio of -2.40 and a beta of 2.21. The company has a 50-day simple moving average of $9.04 and a two-hundred day simple moving average of $17.09. Arvinas has a one year low of $5.94 and a one year high of $37.38.

Hedge Funds Weigh In On Arvinas

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Arvinas by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company's stock valued at $135,389,000 after acquiring an additional 56,561 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Arvinas by 6.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock valued at $78,656,000 after acquiring an additional 249,295 shares during the last quarter. RTW Investments LP lifted its holdings in shares of Arvinas by 19.8% in the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after acquiring an additional 551,979 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Arvinas in the 4th quarter valued at about $42,332,000. Finally, ArrowMark Colorado Holdings LLC grew its position in shares of Arvinas by 42.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,776,555 shares of the company's stock worth $34,057,000 after buying an additional 532,105 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Arvinas

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This represents a 7.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. This represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,230 shares of company stock valued at $769,402. 5.23% of the stock is owned by insiders.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.